166 related articles for article (PubMed ID: 31255479)
21. Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes.
Gencer B; Rodondi N; Auer R; Räber L; Klingenberg R; Nanchen D; Carballo D; Vogt P; Carballo S; Meyer P; Matter CM; Windecker S; Lüscher TF; Mach F
Eur J Intern Med; 2015 Jan; 26(1):56-62. PubMed ID: 25582072
[TBL] [Abstract][Full Text] [Related]
22. Use of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease Program.
Bainey KR; Armstrong PW; Fonarow GC; Cannon CP; Hernandez AF; Peterson ED; Peacock WF; Laskey WK; Zhao X; Schwamm LH; Bhatt DL
Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):227-35. PubMed ID: 24569634
[TBL] [Abstract][Full Text] [Related]
23. Management and outcomes of patients with acute coronary syndromes in Australia and New Zealand, 2000-2007.
Aliprandi-Costa B; Ranasinghe I; Chow V; Kapila S; Juergens C; Devlin G; Elliott J; Lefkowitz J; Brieger DB
Med J Aust; 2011 Aug; 195(3):116-21. PubMed ID: 21806528
[TBL] [Abstract][Full Text] [Related]
24. Effect of a smartphone-based intervention on secondary prevention medication prescriptions after coronary artery bypass graft surgery: The MISSION-1 randomized controlled trial.
Qu J; Du J; Rao C; Chen S; Gu D; Li J; Zhang H; Zhao Y; Hu S; Zheng Z;
Am Heart J; 2021 Jul; 237():79-89. PubMed ID: 33689732
[TBL] [Abstract][Full Text] [Related]
25. What is the Optimal Rate of Invasive Coronary Angiography After Acute Coronary Syndrome? (ANZACS-QI 22).
Chan D; Ghazali S; Selak V; Lee M; Scott T; Kerr A
Heart Lung Circ; 2020 Feb; 29(2):262-271. PubMed ID: 30922552
[TBL] [Abstract][Full Text] [Related]
26. Utilisation and maintenance of high-intensity statins following acute coronary syndrome and coronary angiography: opportunities to improve care (ANZACS-QI 26).
Kerr AJ; Mitnala S; Lee M; White HD
N Z Med J; 2020 Mar; 133(1511):21-40. PubMed ID: 32161419
[TBL] [Abstract][Full Text] [Related]
27. Self-reported use of evidence-based medicine and smoking cessation 6 - 9 months after acute coronary syndrome: a single-centre perspective.
Griffiths B; Lesosky M; Ntsekhe M
S Afr Med J; 2014 Jun; 104(7):483-7. PubMed ID: 25214049
[TBL] [Abstract][Full Text] [Related]
28. Utilization of secondary prevention therapies in patients with nonobstructive coronary artery disease identified during cardiac catheterization: insights from the National Cardiovascular Data Registry Cath-PCI Registry.
Maddox TM; Ho PM; Roe M; Dai D; Tsai TT; Rumsfeld JS
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):632-41. PubMed ID: 20923997
[TBL] [Abstract][Full Text] [Related]
29. Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66).
Foo FS; Lee M; Poppe KK; Clare GC; Stiles MK; Gavin A; Webber M; Jackson R; Kerr AJ
Heart Lung Circ; 2022 Nov; 31(11):1531-1538. PubMed ID: 35999128
[TBL] [Abstract][Full Text] [Related]
30. Rationale and design of a randomized cluster trial to improve guideline-adherence of secondary preventive drugs prescription after coronary artery bypass grafting in China: Measurement and Improvement Studies of Surgical Coronary Revascularization: Secondary Prevention (MISSION-1) Study.
Rao C; Du J; Li X; Li J; Zhang H; Zhao Y; Hu S; Jiang L; Zheng Z;
Am Heart J; 2016 Aug; 178():9-18. PubMed ID: 27502847
[TBL] [Abstract][Full Text] [Related]
31. Demographic differences in the initiation and maintenance of statins in the first year post ACS in New Zealand: a data linkage study (ANZACS-QI 57).
Muniandy A; Lee M; Grey C; Ferrier K; Kerr AJ
N Z Med J; 2021 Apr; 134(1534):31-45. PubMed ID: 33927436
[TBL] [Abstract][Full Text] [Related]
32. Impact of Optimal Medical Therapy at Discharge on One-year Direct Medical Costs in Patients with Acute Coronary Syndromes: A Retrospective, Observational Database Analysis in China.
He X; Wang Y; Cong H; Lu C; Wu J
Clin Ther; 2019 Mar; 41(3):456-465.e2. PubMed ID: 30770126
[TBL] [Abstract][Full Text] [Related]
33. Clinical Characteristics and Burden of Risk Factors Among Patients With Early Onset Acute Coronary Syndromes: The ANZACS-QI New Zealand National Cohort (ANZACS-QI 17).
Earle NJ; Poppe KK; Doughty RN; Rolleston A; Kerr AJ; Legget ME
Heart Lung Circ; 2018 May; 27(5):568-575. PubMed ID: 28606608
[TBL] [Abstract][Full Text] [Related]
34. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
35. National variation in coronary angiography rates and timing after an acute coronary syndrome in New Zealand (ANZACS-QI 6).
Williams MJ; Harding SA; Devlin G; Nunn C; El-Jack S; Scott T; Lee M; Kerr AJ;
N Z Med J; 2016 Jan; 129(1428):66-78. PubMed ID: 26914194
[TBL] [Abstract][Full Text] [Related]
36. Initiation of and long-term adherence to secondary preventive drugs after acute myocardial infarction.
Halvorsen S; Jortveit J; Hasvold P; Thuresson M; Øie E
BMC Cardiovasc Disord; 2016 May; 16():115. PubMed ID: 27246583
[TBL] [Abstract][Full Text] [Related]
37. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
[TBL] [Abstract][Full Text] [Related]
38. The All New Zealand Acute Coronary Syndrome Quality Improvement Programme: Implementation, Methodology and Cohorts (ANZACS-QI 9).
Kerr A; Williams MJ; White H; Doughty R; Nunn C; Devlin G; Grey C; Lee M; Flynn C; Rhodes M; Sutherland K; Wells S; Jackson R; Stewart R
N Z Med J; 2016 Aug; 129(1439):23-36. PubMed ID: 27507719
[TBL] [Abstract][Full Text] [Related]
39. An Economic Evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry Program (ANZACS-QI 28).
Lee P; Zomer E; Liew D
Heart Lung Circ; 2020 Jul; 29(7):1046-1053. PubMed ID: 31537440
[TBL] [Abstract][Full Text] [Related]
40. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.
Yan AT; Yan RT; Tan M; Huynh T; Soghrati K; Brunner LJ; DeYoung P; Fitchett DH; Langer A; Goodman SG;
Am Heart J; 2007 Dec; 154(6):1108-15. PubMed ID: 18035083
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
